BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, June 24, 2025
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 3, 2007
View Archived Issues
Fate Tempts VCs With Viable Stem Cell Business Model
Amid a flurry of stem cell news, Fate Therapeutics raised $12 million in a Series A financing to pursue in vivo and ex vivo modulation of adult stem cells. (BioWorld Today)
Read More
Panel: FDA's Science 'Weak'; Increased Funding Needed
Read More
New Discoveries May Aid HIV Prevention, Treatment
Read More
FDA Amendments Act - Detrimental To Advertising Prescription Drug
Read More
Financings Roundup
Read More
Other News To Note
Read More
Clinic Roundup
Read More
Appointments And Advancements
Read More
